Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.

CONCLUSION: The SVR rate was 42% with telaprevir- or boceprevir-based triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse. PMID: 28469811 [PubMed - in process]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research